[AGTC] Applied Genetic Technologies Corporation


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 9.95 Change: 0.45 (4.74%)
Ext. hours: Change: 0 (0%)

chart AGTC

Refresh chart

Description: Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company?s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma. The company was founded in 1999 and is headquartered in Alachua, Florida.

Fundamental Ratios
Shares Outstanding EPS0.41 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 129.03% Sales Growth - Q/Q-56.44% P/E12.32
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.62% ROE-22.5% ROI
Current Ratio17.17 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin-1185.67% Net Profit Margin-1182.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities32.16 M Cash From Investing Activities16.78 M Cash From Operating Activities-13.08 M Gross Profit
Net Profit-6.33 M Operating Profit-6.39 M Total Assets96.58 M Total Current Assets65.11 M
Total Current Liabilities3.79 M Total Debt Total Liabilities3.79 M Total Revenue280 K
Technical Data
High 52 week10.05 Low 52 week3.4 Last close4.2 Last change-2.33%
RSI67.86 Average true range0.21 Beta1.51 Volume53.6 K
Simple moving average 20 days8.53% Simple moving average 50 days10.66% Simple moving average 200 days-9.89%
Performance Data
Performance Week-2.33% Performance Month16.67% Performance Quart7.69% Performance Half-14.29%
Performance Year-54.59% Performance Year-to-date16.67% Volatility daily2.87% Volatility weekly6.41%
Volatility monthly13.14% Volatility yearly45.51% Relative Volume237.74% Average Volume104.71 K
New High New Low


2019-12-03 07:59:26 | The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

2019-12-02 16:35:10 | AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020

2019-11-13 12:34:48 | Edited Transcript of AGTC earnings conference call or presentation 12-Nov-19 9:30pm GMT

2019-11-12 17:55:10 | Applied Genetic Technologies AGTC Reports Q1 Loss, Lags Revenue Estimates

2019-11-12 16:01:00 | AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2019

2019-11-06 07:00:00 | AGTC to Host First Quarter Results Conference Call and Webcast on November 12, 2019

2019-11-05 07:00:00 | AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program and Reports Compelling Preclinical Data Supporting the Potential of its Dual-Vector Technology

2019-10-31 06:38:19 | We Think Applied Genetic Technologies NASDAQ:AGTC Can Afford To Drive Business Growth

2019-10-21 07:00:05 | AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies

2019-10-01 07:30:00 | AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

2019-09-30 12:03:32 | Applied Genetic Notches Sell-Side Upgrade After Releasing Interim Study Data

2019-09-27 19:59:26 | Edited Transcript of AGTC earnings conference call or presentation 26-Sep-19 8:30pm GMT

2019-09-26 17:35:09 | Applied Genetic Technologies AGTC Reports Q4 Loss, Lags Revenue Estimates

2019-09-26 16:01:00 | AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019

2019-09-26 14:30:00 | Applied Genetic Technologies Corp. to Host Earnings Call

2019-09-25 16:05:00 | AGTC to Present at Upcoming Conferences

2019-09-19 10:30:02 | Analysts Estimate Applied Genetic Technologies AGTC to Report a Decline in Earnings: What to Look Out for

2019-09-18 16:05:00 | AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 26, 2019

2019-09-16 06:23:48 | How Many Applied Genetic Technologies Corporation NASDAQ:AGTC Shares Do Institutions Own?

2019-09-02 10:30:02 | Analysts Estimate Applied Genetic Technologies AGTC to Report a Decline in Earnings: What to Look Out for

2019-08-28 07:00:00 | AGTC to Present at Upcoming Conferences

2019-08-14 07:30:00 | Italian Achromatopsia Association Increases Global Awareness of Achromatopsia, a Rare Genetic Eye Disease, With an Expedition to Pingelap, the Island of the Color Blind

2019-08-07 07:00:00 | AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 14, 2019

2019-07-24 13:54:05 | Alexion ALXN Q2 Earnings Beat Estimates, Guidance Raised

2019-07-23 07:00:00 | AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study

2019-07-19 09:41:01 | Horizon's NDA for Procysbi New Dosage Form Accepted by FDA

2019-07-17 15:33:06 | Is Applied Genetic Technologies Corporation NASDAQ:AGTC Overpaying Its CEO?

2019-07-11 09:05:01 | Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

2019-07-10 17:53:09 | Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

2019-07-10 17:51:09 | Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug

2019-07-08 18:02:10 | ObsEva Ends Recruitment in Second Uterine Fibroids Study

2019-07-05 12:04:04 | Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

2019-06-28 10:10:02 | Novavax NVAX Seeks Accelerated Approval Pathway for NanoFlu

2019-06-25 08:00:12 | Alnylam Presents New Data for RNAi Therapeutic Onpattro

2019-06-25 07:00:00 | AGTC Announces New Leadership Appointments

2019-06-24 17:53:09 | Epizyme Announces Positive Interim Data on Lead Candidate

2019-06-24 17:45:09 | AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire

2019-06-20 09:01:01 | Ultragenyx & Arcturus Therapeutics Expand Existing Agreement

2019-06-18 07:00:00 | AGTC to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference on June 25, 2019

2019-06-17 18:17:10 | Alexion's ALXN PNH Drug Ultomiris Shows Long-Term Efficacy

2019-06-14 17:25:09 | Dr. Reddy's Inks Deal to Sell Neurology Branded Products

2019-06-13 17:46:09 | Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

2019-06-13 10:26:02 | Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230

2019-06-13 09:30:01 | Is Applied Genetic Technologies AGTC Stock Outpacing Its Medical Peers This Year?

2019-06-11 18:18:10 | Novavax' Shares Drop as FDA Advises Another Study for Resvax

2019-06-04 16:16:08 | bluebird's Zynteglo Gets EU Conditional Marketing Approval

2019-06-03 16:48:08 | Alnylam Initiates Phase I Study on Hypertension Candidate

2019-05-29 10:40:02 | Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

2019-05-28 09:02:01 | Epizyme EPZM Shares Surge More Than 100% YTD: Here's Why?

2019-05-27 05:00:09 | Dynavax DVAX to Cut Jobs and Focus on Vaccine Business